Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.06.012
- Author:
Fan-Cong KONG
1
;
Ling QI
1
;
Wen-Feng HUANG
1
;
Min YU
1
;
Yu-Lan ZHOU
1
;
De-Xiang JI
1
;
Fei LI
2
Author Information
1. Center of Hematology, The First Affiliated Hospital of Nanchang University, Jiangxi Clinical Research Center for Hematologic Disease, Nanchang 330006, Jiangxi Province, China.
2. Center of Hematology, The First Affiliated Hospital of Nanchang University, Jiangxi Clinical Research Center for Hematologic Disease, Nanchang 330006, Jiangxi Province, China,E-mail: yx021021@sina.com.
- Publication Type:Journal Article
- Keywords:
acute myeloid leukemia;
efficacy;
survival;
venetoclax
- MeSH:
Humans;
Middle Aged;
Aged;
Aged, 80 and over;
Retrospective Studies;
Nucleophosmin;
Bridged Bicyclo Compounds, Heterocyclic/adverse effects*;
Leukemia, Myeloid, Acute/genetics*;
Recurrence;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
- From:
Journal of Experimental Hematology
2023;31(6):1676-1683
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the efficacy and survival of venetoclax based (VEN-based) regimen in the treatment of acute myeloid leukemia（AML）.
METHODS:A retrospective study was conducted in patients who received VEN-based regimen and completed at least 1 course of efficacy evaluation at the The First Affiliated Hospital of Nanchang University from July 2019 to July 2022. The incidence of complete remission （CR）/CR with incomplete hematologic recovery （CRi） rate, objective remission rate（ORR） and survival of patients with different risk strati- fication and gene subtypes were analyzed.
RESULTS:A total of 79 patients were enrolled, including 43 patients with newly diagnosed unfit AML （unfit AML） and 36 relapsed/refractory AML (R/R AML). The median age of the patients was 62(14-83) years old. 36 out of 79 patients achieved CR/CRi and the ORR of the whole cohort was 64.6%. The CR/CRi rate of unfit AML patients was significantly higher than that of R/R AML patients (60.5% vs 27.8%, P=0.004). In unfit AML cohort, the patients with NPM1 and IDH1/2 mutations were benefited, 8 out of 9 patients ahcieved CR/CRi, 7/8 and 5/8 patients achieved minimal residual disease (MRD) negativity, respectively. Six out of 9 patients with TET2 mutation achieved CR/CRi, 3/6 patients achieved MRD negativity. In R/R AML cohort, 2 out of 3 patients with RUNX1 mutation achieved CR/CRi, without MRD negative, while the CR/CRi rate of patients with other gene mutations was lower than 40%. The median follow-up time was 10.1(95%CI: 8.6-11.6) months. In whole cohort, the median overall survival (mOS) time was 9.1 months and the relapse free survival (RFS) time was not reached. The mOS and RFS of unfit AML patients were significantly longer than those of R/R AML patients (14.1 vs 6.8 months, P=0.013; not reached vs 3.3 months, P=0.000). In unfit AML cohort, the mOS of patients with NPM1 or IDH1/2 mutations was not reached, while that of patients without NPM1 or IDH1/2 mutations was 8.0 months (P=0.009; P=0.022). Furthermore, the mOS of patients with TP53 mutaion was significantly shorter than that of patients without TP53 mutation (5.2 vs 14.1 months， P=0.049). In R/R AML cohort, there was no significant difference in mOS between patients with mutation in each gene subtype and those without gene mutation (P>0.05). All patients had hematology adverse reactions, 91.1% patients had AE grade≥3. The most common non-hematology adverse reactions was infection, with an incidence of 91.1%. VEN-based regimen was tolerable for AML patients.
CONCLUSION:VEN-based regimen can achieve a high response rate, especially in unfit AML with acceptable safety, and some patients can achieve MRD negative. It is also effective in NPM1-, IDH1/2-positive patients with long survival time.
